Significant impairment in immune recovery after cancer treatment

Nursing Research

Volumn 58, Issue 2, 2009, Pages 105-114

  Kang, Duck Hee ^a   Weaver, Michael T ^b   Park, Na Jin ^a   Smith, Barbara ^c   McArdle, Trad ^a   Carpenter, John ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cancer treatment; Immune recovery

Indexed keywords

CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TIME; UNITED STATES;

ADULT; AGED; ANTIGENS, CD4; ANTIGENS, CD56; ANTIGENS, CD8; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1ALPHA; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LINEAR MODELS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECOVERY OF FUNCTION; SOUTHEASTERN UNITED STATES; TIME FACTORS;

EID: 63549143753     PISSN: 00296562     EISSN: None     Source Type: Journal    
DOI: 10.1097/NNR.0b013e31818fcecd     Document Type: Article

References (41)

1. American Cancer Society. (2007). Cancer facts and figures. Atlanta: GA: Author.
2. Arduino, S., Tessarolo, M., Bellino, R., Colombatto, S., Leo, L., Wierdis, T., et al. (1996). Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse. European Journal of Gynaecological Oncology, 17(6), 535-537.
3. Avigan, D., Wu, Z., Joyce, R., Elias, A., Richardson, P., McDermott, D., et al. (2000). Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplantation, 26(2), 169-176.
4. Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J. Y. (2003). Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British Journal of Cancer, 88(11), 1721-1726.
5. Beitsch, P., Lotzova, E., Hortobagyi, G., & Pollock, R. (1994). Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surgical Oncology, 3(4), 211-219.
6. Belka, C., Ottinger, H., Kreuzfelder, E., Weinmann, M., Lindemann, M., Lepple-Wienhues, A., et al. (1999). Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiotherapy and Oncology, 50(2), 199-204.
7. Bozcuk, H., Uslu, G., Samur, M., Yildiz, M., Ozben, T., Ozdogan, M., et al. (2004). Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine, 27(2-3), 58-65.
8. Brenner, B. G., Gryllis, C., Gornitsky, M., Cupples, W., & Wainberg, M. (1991). Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations. Anticancer Research, 11, 969-974.
9. Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996). Natural killer cells and cancer. Cancer, 77(7), 1226-1243.
10. Campbell, M. J., Scott, J., Maecker, H. T., Park, J. W., & Esserman, L. J. (2005). Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Research and Treatment, 91(2), 163-171.
11. Caras, I., Grigorescu, A., Stavaru, C., Radu, D. L., Mogos, I., Szegli, G., et al. (2004). Evidence for immune defects in breast and lung cancer patients. Cancer Immunology and lmmunotherapy, 53(12), 1146-1152.
12. Elsasser-Beile, U., von Kleist, S., & Gallati, H. (1991). Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. Journal of Immunological Methods, 139(2), 191-195.
13. Elsasser-Beile, U., von Kleist, S., Sauther, W., Gallati, H., & Monting, J. S. (1993). Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. British Journal of Cancer, 68(1), 32-36.
14. Gardner, R. V. (1999). Long term hematopoietic damage after chemotherapy and cytokine. Frontiers in Bioscience, 4, e47-e57.
15. Head, J. F., Elliott, R. L., & McCoy, J. L. (1993). Evaluation of lymphocyte immunity in breast cancer patients. Breast Cancer Research and Treatment, 26(1), 77-88.
16. Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., et al. (2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology, 21(6), 976-983.
17. Hintze, J. (2008). PASS 2008. Kaysville, UT: NCSS.
18. Kang, D. H., Coe, C. L., & McCarthy, D. O. (1996). Academic examinations significantly impact immune responses, but not lung function, in healthy and well-managed asthmatic adolescents. Brain, Behavior, and Immunity, 10(2), 164-181.
19. Kang, D. H., Coe, C. L., McCarthy, D. C., & Ershler, W. B. (1997). Immune responses to final exams in healthy and asthmatic adolescents. Nursing Research, 46(1), 12-19.
20. Konjevic, G., & Spuzic, I. (1993). Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma, 40(2), 81-85.
21. Lissoni, P., Barni, S., Rovelli, F., & Tancini, G. (1991). Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology, 48(2), 125-127.
22. Little, T., Schnabel, K., & Baumert, J. (2000). Modeling longitudinal and multilevel data: Practical issues, applied approaches, and specific examples. Mahwah, NJ: Lawrence Erlbaum Associates.
23. McCullagh, P., & Nelder, J. A. (1997). Generalized linear models (2nd ed.). New York: Chapman & Hall CRC.
24. McCulloch, C., & Searle, S. (2001). Generalized, linear, and mixed models. New York: John Wiley & Sons.
25. Nagao, F. N., Yabe, T., Xu, M., & OkuMura, K. (1995). Phenotypical and functional analyses of natural killer cells from low NK activity individuals among healthy and patient populations. Natural Immunity, 14, 225-233.
26. Nieto, Y., Shpall, E. J., McNiece, I. K., Nawaz, S., Beaudet, J., Rosinski, S., et al. (2004). Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clinical Cancer Research, 10(15), 5076-5086.
27. Porrata, L. F., Ingle, J. N., Litzow, M. R., Geyer, S., & Markovic, S. N. (2001). Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplantation, 28(9), 865-871.
28. Pross, H. F., & Lotzova, E. (1993). Role of natural killer cells in cancer. Natural Immunity, 12(4-5), 279-292.
29. Sachs, G., Rasoul-Rockenschaub, S., Aschauer, H., Spiess, K., Gober, I., Staffen, A., et al. (1995). Lytic effector cell activity and major depressive disorder in patients with breast cancer: A prospective study. Journal of Neuroimmunology, 59(1-2), 83-89.
30. Santin, A. D., Hermonat, P. L., Ravaggi, A., Bellone, S., Roman, J., Pecorelli, S., et al. (2000). Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal of Radiation Oncology, Biology, and Physics, 48(4), 997-1006.
31. SAS Institute Inc. (2005). The GLIMMIX procedure. Cary, NC: Author.
32. Sephton, S. E., Sapolsky, R. M., Kraemer, H. C., & Spiegel, D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute, 92(12), 994-1000.
33. Sewell, H. F., Halbert, C. F., Robins, R. A., Galvin, A., Chan, S., & Blarney, R. W. (1993). Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. International Journal of Cancer, 55(5), 735-738.
34. Sinkovics, J. G., & Horvath, J. C. (2005). Human natural killer cells: A comprehensive review. International Journal of Oncology, 27(1), 5-47.
35. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.
36. Solomayer, E. F., Feuerer, M., Bai, L., Umansky, V., Beckhove, P., Meyberg, G. C., et al. (2003). Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clinical Cancer Research, 9(1), 174-180.
37. Steele, T. A. (2002). Chemotherapy-induced immunosuppression and reconstitution of immune function. Leukemia Research, 26(4), 411-414.
38. van der Most, R. G., Currie, A., Robinson, B. W., & Lake, R. A. (2006). Cranking the immunologic engine with chemotherapy: Using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Research, 66(2), 601-604.
39. Verastegui, E. L., Morales, R. B., Barrera-Franco, J. L., Poitevin, A. C., & Hadden, J. (2003). Long-term immune dysfunction after radiotherapy to the head and neck area. International Immunopharmacology, 3(8), 1093-1104.
40. Whiteside, T. L., & Herberman, R. B. (1995). The role of natural killer cells in immune surveillance of cancer. Current Opinion in Immunology, 7(5), 704-710.
41. Wiltschke, C., Krainer, M., Budinsky, A. C., Berger, A., Muller, C., Zeillinger, R., et al. (1995). Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: A prospective longitudinal study. British Journal of Cancer, 71(6), 1292-1296.